Literature DB >> 15519912

Antiepileptic drug treatment in seizure-free mesial temporal lobe epilepsy patients with hippocampal sclerosis following selective amygdalohippocampectomy.

Heinz Gregor Wieser1, Adrian Häne.   

Abstract

UNLABELLED: Retrospectively we analysed postoperative AED treatment in patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS) who were seizure free following selective amygdalohippocampectomy (AHE). In this subgroup, we compared the patients without AEDs with that in the entire series.
RESULTS: During the year prior to surgery, in the MTLE-HS group, a mean of 2.3 +/- 0.8 AEDs were taken. The percentage of seizure-free MTLE-HS patients without AEDs increases to 40% from the postoperative year 5 on. In the ILAE Class 1a (seizure- and aura-free since surgery) at postoperative year 5 more than 60% and from postoperative year 7 on more than 90% have discontinued AED intake.
CONCLUSION: These figures indicate that reduction and discontinuation of AEDs is the same in the subgroup "seizure-free MTLE-HS patients" compared to the entire series.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519912     DOI: 10.1016/j.seizure.2003.12.010

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

Review 1.  A Mesiotemporal Lobe Epilepsy Mouse Model.

Authors:  Duveau Venceslas; Roucard Corinne
Journal:  Neurochem Res       Date:  2017-03-23       Impact factor: 3.996

2.  Predictors of prognosis in patients with temporal lobe epilepsy after anterior temporal lobectomy.

Authors:  Zhenxing Sun; Huancong Zuo; Dan Yuan; Yaxing Sun; Kai Zhang; Zhiqiang Cui; Jin Wang
Journal:  Exp Ther Med       Date:  2015-09-18       Impact factor: 2.447

3.  Strategies for promoting anti-seizure effects of hippocampal fetal cells grafted into the hippocampus of rats exhibiting chronic temporal lobe epilepsy.

Authors:  Muddanna S Rao; Bharathi Hattiangady; Kiranmai S Rai; Ashok K Shetty
Journal:  Neurobiol Dis       Date:  2007-05-23       Impact factor: 5.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.